Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical company specializing in PhotoPoint(TM) photodynamic therapy (PDT), today announced novel results for the prevention of vascular access graft failure, which commonly occurs in hemodialysis patients. In two preclinical studies presented at the Cardiovascular Radiation Therapy (CRT) meeting, Washington DC, PhotoPoint PDT significantly inhibited problematic cell proliferation in a synthetic (ePTFE) vascular access graft failure model.
“The results were quite encouraging and, if they can be realized in clinical trials, could make a dramatic difference in our ability to maintain vascular access in hemodialysis patients,” stated Julie A. Freischlag, M.D., Chief of Vascular Surgery, UCLA Medical School, whose laboratory participated in the study. “This therapy has the advantage of being locally applied and could make a significant difference in arteriovenous graft failure rates, a major unmet medical problem.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!